PIA
RVNC

Piedmont Investment Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Piedmont Investment Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-570
Closed -$16K – 2375
2018
Q2 		$16K Buy
+570
New +$17.1K ﹤0.01% 1660

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Piedmont Investment Advisors's RVNC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2018, closing a stake of 570 shares — an estimated $16K sold.

Piedmont Investment Advisors first reported a position in RVNC in Q2 2018 and held it in 1 quarter. The position peaked at $16K in Q2 2018. 110 funds tracked by Wall St. Rank hold RVNC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 570 Revance Therapeutics, Inc. shares in Q3 2018, an estimated $16K.
  • Piedmont Investment Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Revance Therapeutics, Inc. position peaked at $16K in Q2 2018.
  • 110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.